OA12460A - Recovery of enzyme activity from enveloped viruses. - Google Patents

Recovery of enzyme activity from enveloped viruses. Download PDF

Info

Publication number: OA12460A
Authority: OA; OAPI
Prior art keywords: virus; activity; substance; cysteine; plasma
Prior art date: 2001-04-05

Application number

OA1200300243A

Other languages

English (en)

Inventor

Tommy Gatu

Simon Gronowitz

Clas Kallander

Original Assignee

Cavidi Tech Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-05

Filing date

2002-03-27

Publication date

2006-05-24

2002-03-27 Application filed by Cavidi Tech Ab filed Critical Cavidi Tech Ab

2006-05-24 Publication of OA12460A publication Critical patent/OA12460A/en

Links

230000000694 effects Effects 0.000 title claims abstract description 82
241000700605 Viruses Species 0.000 title claims abstract description 61
102000004190 Enzymes Human genes 0.000 title claims abstract description 51
108090000790 Enzymes Proteins 0.000 title claims abstract description 51
238000011084 recovery Methods 0.000 title claims abstract description 11
102100034343 Integrase Human genes 0.000 claims abstract description 109
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 109
239000000126 substance Substances 0.000 claims abstract description 50
238000000034 method Methods 0.000 claims abstract description 32
108010003533 Viral Envelope Proteins Proteins 0.000 claims abstract description 11
239000012472 biological sample Substances 0.000 claims abstract description 5
239000002245 particle Substances 0.000 claims abstract description 3
239000000523 sample Substances 0.000 claims description 24
239000000872 buffer Substances 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 13
238000011534 incubation Methods 0.000 claims description 13
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 13
229940033663 thimerosal Drugs 0.000 claims description 13
230000003612 virological effect Effects 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 9
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 8
235000018417 cysteine Nutrition 0.000 claims description 8
229960003151 mercaptamine Drugs 0.000 claims description 8
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 claims description 6
239000003638 chemical reducing agent Substances 0.000 claims description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
230000000415 inactivating effect Effects 0.000 claims description 6
230000002934 lysing effect Effects 0.000 claims description 6
NBCQBGBECVUZMK-UHFFFAOYSA-N (4-carboxyphenyl)mercury;hydrate Chemical compound O.OC(=O)C1=CC=C([Hg])C=C1 NBCQBGBECVUZMK-UHFFFAOYSA-N 0.000 claims description 5
230000009089 cytolysis Effects 0.000 claims description 5
239000003599 detergent Substances 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 claims description 4
241001430294 unidentified retrovirus Species 0.000 claims description 4
108010024636 Glutathione Proteins 0.000 claims description 3
241000713666 Lentivirus Species 0.000 claims description 3
229960003180 glutathione Drugs 0.000 claims description 3
WCKKVBDZUVPNNY-UHFFFAOYSA-N 2-(2-aminoethylsulfonylsulfanyl)ethanamine Chemical compound NCCSS(=O)(=O)CCN WCKKVBDZUVPNNY-UHFFFAOYSA-N 0.000 claims description 2
150000001450 anions Chemical group 0.000 claims description 2
238000001952 enzyme assay Methods 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 claims 1
230000002779 inactivation Effects 0.000 abstract description 6
239000000499 gel Substances 0.000 description 26
238000002976 reverse transcriptase assay Methods 0.000 description 13
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
230000001413 cellular effect Effects 0.000 description 9
210000002845 virion Anatomy 0.000 description 9
MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
238000010586 diagram Methods 0.000 description 7
230000001177 retroviral effect Effects 0.000 description 7
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000881705 Porcine endogenous retrovirus Species 0.000 description 5
238000011002 quantification Methods 0.000 description 5
125000003396 thiol group Chemical group [H]S* 0.000 description 5
238000007792 addition Methods 0.000 description 4
244000309466 calf Species 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000003750 conditioning effect Effects 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
239000002002 slurry Substances 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
210000004779 membrane envelope Anatomy 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000012552 review Methods 0.000 description 3
238000013207 serial dilution Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000712907 Retroviridae Species 0.000 description 2
XYONNSVDNIRXKZ-UHFFFAOYSA-N S-methyl methanethiosulfonate Chemical compound CSS(C)(=O)=O XYONNSVDNIRXKZ-UHFFFAOYSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
229940096826 phenylmercuric acetate Drugs 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
241000712892 Arenaviridae Species 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241001493147 Bwamba orthobunyavirus Species 0.000 description 1
241001493160 California encephalitis virus Species 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
102000001996 DNA Polymerase beta Human genes 0.000 description 1
108010001132 DNA Polymerase beta Proteins 0.000 description 1
102000004214 DNA polymerase A Human genes 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241001115402 Ebolavirus Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000711950 Filoviridae Species 0.000 description 1
239000012541 Fractogel® Substances 0.000 description 1
239000012554 Fractogel® EMD TMAE Hicap (M) Substances 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
241000713326 Jaagsiekte sheep retrovirus Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001115401 Marburgvirus Species 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
241000712464 Orthomyxoviridae Species 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000150350 Peribunyaviridae Species 0.000 description 1
241000255129 Phlebotominae Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700625 Poxviridae Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000000705 Rift Valley Fever Diseases 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000710924 Togaviridae Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000032823 cell division Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
150000005338 nitrobenzoic acids Chemical class 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Enzymes And Modification Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

OA1200300243A 2001-04-05 2002-03-27 Recovery of enzyme activity from enveloped viruses. OA12460A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0101219A SE0101219D0 (sv)	2001-04-05	2001-04-05	Recovery of enzyme activity from enveloped viruses

Publications (1)

Publication Number	Publication Date
OA12460A true OA12460A (en)	2006-05-24

Family

ID=20283685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300243A OA12460A (en)	2001-04-05	2002-03-27	Recovery of enzyme activity from enveloped viruses.

Country Status (17)

Country	Link
US (1)	US7566529B2 (de)
EP (1)	EP1373897B1 (de)
JP (1)	JP4364512B2 (de)
CN (1)	CN1255550C (de)
AP (1)	AP1823A (de)
AT (1)	ATE410689T1 (de)
AU (1)	AU2002249715B8 (de)
BR (1)	BRPI0208542B8 (de)
DE (1)	DE60229222D1 (de)
EA (1)	EA006740B1 (de)
ES (1)	ES2315357T3 (de)
MX (1)	MXPA03009060A (de)
OA (1)	OA12460A (de)
PT (1)	PT1373897E (de)
SE (1)	SE0101219D0 (de)
WO (1)	WO2002082088A1 (de)
ZA (1)	ZA200307413B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1808697A1 (de) *	2006-01-13	2007-07-18	Novartis Vaccines and Diagnostics, Inc.	Verwendung einer Ionenaustauschmatrix zur Bestimmung der Konzentration von Viruspartikeln und/oder Virusantigenen
WO2016115484A1 (en) *	2015-01-16	2016-07-21	Takeda Vaccines, Inc.	Detection of particle-contained reverse transcriptase activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707439A (en) *	1984-10-26	1987-11-17	The United States Of America As Represented By The Department Of Health And Human Services	Screening test for reverse-transcriptase containing virus such as non-A, non-B hepatitis, NANBH
SE0001132D0 (sv) *	2000-03-29	2000-03-29	Cavidi Tech Ab	Method of concentrating and recovering a viral enzyme activity from biological samples

2001
- 2001-04-05 SE SE0101219A patent/SE0101219D0/xx unknown
2002
- 2002-03-27 AT AT02718732T patent/ATE410689T1/de active
- 2002-03-27 WO PCT/SE2002/000612 patent/WO2002082088A1/en not_active Ceased
- 2002-03-27 OA OA1200300243A patent/OA12460A/en unknown
- 2002-03-27 EP EP02718732A patent/EP1373897B1/de not_active Expired - Lifetime
- 2002-03-27 CN CNB028110889A patent/CN1255550C/zh not_active Expired - Fee Related
- 2002-03-27 US US10/472,756 patent/US7566529B2/en not_active Expired - Lifetime
- 2002-03-27 EA EA200300961A patent/EA006740B1/ru not_active IP Right Cessation
- 2002-03-27 DE DE60229222T patent/DE60229222D1/de not_active Expired - Lifetime
- 2002-03-27 AU AU2002249715A patent/AU2002249715B8/en not_active Ceased
- 2002-03-27 JP JP2002579807A patent/JP4364512B2/ja not_active Expired - Fee Related
- 2002-03-27 ES ES02718732T patent/ES2315357T3/es not_active Expired - Lifetime
- 2002-03-27 PT PT02718732T patent/PT1373897E/pt unknown
- 2002-03-27 MX MXPA03009060A patent/MXPA03009060A/es active IP Right Grant
- 2002-03-27 AP APAP/P/2003/002893A patent/AP1823A/en active
- 2002-03-27 BR BRPI0208542A patent/BRPI0208542B8/pt not_active IP Right Cessation
2003
- 2003-09-23 ZA ZA200307413A patent/ZA200307413B/en unknown

Also Published As

Publication number	Publication date
AU2002249715B8 (en)	2006-12-07
HK1063073A1 (en)	2004-12-10
EP1373897A1 (de)	2004-01-02
JP4364512B2 (ja)	2009-11-18
ZA200307413B (en)	2004-09-23
ES2315357T3 (es)	2009-04-01
BRPI0208542B8 (pt)	2021-07-27
US7566529B2 (en)	2009-07-28
CN1255550C (zh)	2006-05-10
EA006740B1 (ru)	2006-04-28
MXPA03009060A (es)	2004-02-17
AP1823A (en)	2008-01-31
BR0208542A (pt)	2004-03-02
SE0101219D0 (sv)	2001-04-05
BR0208542B1 (pt)	2014-06-17
CN1513116A (zh)	2004-07-14
AU2002249715B2 (en)	2006-10-19
EP1373897B1 (de)	2008-10-08
WO2002082088A1 (en)	2002-10-17
JP2004527246A (ja)	2004-09-09
AP2003002893A0 (en)	2003-12-31
PT1373897E (pt)	2008-12-31
EA200300961A1 (ru)	2004-04-29
ATE410689T1 (de)	2008-10-15
DE60229222D1 (de)	2008-11-20
US20040110265A1 (en)	2004-06-10

Publication	Publication Date	Title
Towner et al.	2006	Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola
Quadt et al.	1993	Characterization of a host protein associated with brome mosaic virus RNA-dependent RNA polymerase.
Arai et al.	2008	Phylogenetically distinct hantaviruses in the masked shrew (Sorex cinereus) and dusky shrew (Sorex monticolus) in the United States
Boyer et al.	2012	HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors
Herrler et al.	1992	A synthetic sialic acid analogue is recognized by influenza C virus as a receptor determinant but is resistant to the receptor-destroying enzyme.
EP0447442B1 (de)	1994-09-21	Verfahren zur polymeraseaktivitätsbestimmung
Steinschneider et al.	1966	Studies of nucleotide sequences in tobacco mosaic virus ribonucleic acid. III. Periodate oxidation and semicarbazone formation
Traub et al.	1976	Isolation and properties of the replicase of encephalomyocarditis virus
Abboud et al.	1979	The DNA polymerases associated with the adenovirus type 2 replication complex: effect of 2′-3′-dideoxythymidine-5′-triphosphate on viral DNA synthesis
OA12460A (en)	2006-05-24	Recovery of enzyme activity from enveloped viruses.
JP6522606B2 (ja)	2019-05-29	乾燥血斑からの細胞遊離性ウイルス粒子の測定方法
AU2002249715A1 (en)	2003-04-10	Recovery of enzyme activity from enveloped viruses
HK1063073B (en)	2009-12-31	Recovery of enzyme activity from enveloped viruses
Lima et al.	2014	A technique combining immunoprecipitation and RT‐PCR for RNA plant virus detection
SE0001132D0 (sv)	2000-03-29	Method of concentrating and recovering a viral enzyme activity from biological samples
Okita et al.	1977	The deoxyribonucleic acid polymerases from the diatom Cylindrotheca fusiformis. Partial purification and characterization of four distinct activities
JP4455054B2 (ja)	2010-04-21	ウイルス薬剤感受性の検査法
Chandra et al.	1980	RNA-dependent DNA polymerase activity in ocular granulocytic sarcoma associated to acute myelomonocytic leukemia in Turkish children. Biochemical and immunological characterization of the enzyme
Tannock et al.	1975	Degradation of myxovirus virion RNA by periodate